What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

To explore the tolerability of emicizumab injections in people with hemophilia A across multiple clinical studies.

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

To explore the tolerability of emicizumab injections in people with hemophilia A across multiple clinical studies.
Analysis included participants from HAVEN 1–4 clinical studies receiving emicizumab.
Participants were divided into groups based on age and FVIII inhibitor status.
Exploratory outcomes assessed included the incidence of injection-site reactions over time.
112 participants (28.1%) experienced at least one injection-site reaction (ISR).
Proportion of participants with ISRs declined to less than 1% over time.
Overall, 0.75% of over 42,000 emicizumab injections were associated with an ISR.

No takes yet. Share an insight, caveat, or question.

Exploratory analysis finds low adverse events in hemophilia A patients receiving emicizumab, suggesting good tolerability over time.

Shannon L. Carpenter (2025) studied this question.

View Full Paper

Ask AI

Bookmark